Effect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic Complication
Impact of Resveratrol and Pharmaceutical Care on Diabetes Mellitus and Its Neuropathic Complication
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Diabetic neuropathy is the most common microvascular complication of diabetes, resulting from prolonged periods of hyperglycemia, damaging fragile nerve fibers and the walls of their blood vessels.
- Despite clinical developments in the treatment of diabetes complications, especially diabetic neuropathy, it still remains a clinical challenge with no effective solution.
- Conventional therapies such as anti-epileptics, opioid analgesics, and antidepressants for the treatment of neuropathic pain are quite challenging due to their serious adverse effects.
- There is a need to investigate novel effective and safe options.
- Recently, polyphenols have also been introduced as potential neuroprotective agents in diabetes.
- Alleviation of the symptoms associated with diabetic neuropathy and exerting preventive measures to halt the emergence of neuropathy complications are crucial priorities, and this requires multidisciplinary approaches including pharmacotherapy and provision of healthcare professional services such as pharmacist intervention.
- Aim of the study: to evaluate the effects of resveratrol and pharmaceutical care on the severity of diabetic neuropathy and improvement in the quality of life of diabetic patients.
- Study design: four-arm randomized, double-blind, placebo-controlled clinical trial.
- Interventions:Therapeutic intervention and Pharmacist intervention.
- Number of participants = 120
- Number of groups = 4 groups each of 30 patients
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Bushra Marouf, PhD
- Phone Number: Dr. 009647701562796
- Email: bushra.marouf@univsul.edu.iq
Study Contact Backup
- Name: Gulabakh Mohammed Amin, Bsc
- Phone Number: 009647708914542
- Email: gullabakh.mohammedamin@univsul.edu.iq
Study Locations
-
-
-
Sulaymānīyah, Iraq, 00964
- College of Pharmacy-University of Sulaimani
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with pain due to bilateral peripheral neuropathy caused by type 2 diabetes mellitus.
- HbA1c of greater than 7%
- The daily pain must be present for at least 6 months, and the diagnosis will be confirmed by a score >4 on the Michigan Neuropathy Screening Instrument (MNSI), Douleur Neuropathique 4 (DN4). The severity of pain when evaluated for the past 24 was ≥4 on the 10 cm Visual Analogue Scale (VAS) at baseline without the use of analgesic for 48 hours.
Exclusion Criteria:
- Older subjects with high risks of cardiovascular diseases,
- Pregnant or breastfeeding,
- Having a prior renal transplant or current renal dialysis,
- Patients have a diagnosis of major depressive disorder, generalized anxiety disorder, heavy alcohol drinkers,
- Significant hepatic or renal disease,
- Patients on antioxidant therapy, or pentoxyphylline within the last month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Resveratrol
Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months.
|
This group received resveratrol with the conventional therapy
|
|
Placebo Comparator: Placebo
Non-interventional group, participants are receiving only Placebo once daily for 3 months. Placebo formulated as capsule match the color and size of the active comparator, |
This group received placebo with the conventional therapy
|
|
Other: Resveratrol plus Pharmaceutical care
Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months with pharmaceutical care.
|
This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
|
|
Other: Placebo with pharmaceutical care
Interventional group, participants are receiving placebo along with pharmaceutical care for 3 months.
|
This group received placebo with Pharmaceutical care in addition to the conventional therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
visual analog scale (VAS)
Time Frame: up to 3 months
|
to assess neuropathic pain, VAS scale ranges between 0-10 , 0 indicates no pain while 10 indicates severe pain.
|
up to 3 months
|
|
Douleur Neuropathique 4 questionnaire (DN4)
Time Frame: up to 3 months
|
to assess the severity of diabetic peripheral neuropathy.
|
up to 3 months
|
|
The Michigan Neuropathy Screening Instrument (MNSI)
Time Frame: up to 3 months
|
to assess the severity of diabetic peripheral neuropathy
|
up to 3 months
|
|
Electroneurography
Time Frame: up to 3 months
|
Motor nerve conduction velocity (m/s), sensory nerve conduction velocity(m/s) will be measured using surface electrodes.
|
up to 3 months
|
|
Assessment of Quality of Life
Time Frame: up to 3 months
|
using the RAND-36 health survey questionnaire
|
up to 3 months
|
|
Serum neopterin levels
Time Frame: up to 3 months
|
biochemical marker for peripheral neuropathy
|
up to 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The mean change in fasting blood glucose
Time Frame: up to 3 months
|
to assess glycemic status
|
up to 3 months
|
|
Mean change of glycated hemoglobin (HbA1c)-mmol/l
Time Frame: up to 3 months
|
to assess glycemic status
|
up to 3 months
|
|
Measurement of serum level of LDL, cholesterol, HDL, Triglyceride
Time Frame: up to 3 months
|
to assess the effect of the interventions on metabolic changes
|
up to 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bushra Marouf, PhD, Department of Pharmacology and Toxicology-College of Pharmacy-University of Sulaimani
Publications and helpful links
General Publications
- Azmi S, ElHadd KT, Nelson A, Chapman A, Bowling FL, Perumbalath A, Lim J, Marshall A, Malik RA, Alam U. Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review. Diabetes Ther. 2019 Feb;10(1):35-56. doi: 10.1007/s13300-018-0550-x. Epub 2018 Dec 18.
- Collins C, Limone BL, Scholle JM, Coleman CI. Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Res Clin Pract. 2011 May;92(2):145-52. doi: 10.1016/j.diabres.2010.09.023. Epub 2010 Oct 20.
- Elbarbary NS, Ismail EAR, El-Hilaly RA, Ahmed FS. Role of neopterin as a biochemical marker for peripheral neuropathy in pediatric patients with type 1 diabetes: Relation to nerve conduction studies. Int Immunopharmacol. 2018 Jun;59:68-75. doi: 10.1016/j.intimp.2018.03.026. Epub 2018 Apr 6.
- Naseri R, Farzaei F, Fakhri S, El-Senduny FF, Altouhamy M, Bahramsoltani R, Ebrahimi F, Rahimi R, Farzaei MH. Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective. Daru. 2019 Dec;27(2):781-798. doi: 10.1007/s40199-019-00289-w. Epub 2019 Jul 27.
- Eid S, Sas KM, Abcouwer SF, Feldman EL, Gardner TW, Pennathur S, Fort PE. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019 Sep;62(9):1539-1549. doi: 10.1007/s00125-019-4959-1. Epub 2019 Jul 25.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Endocrine System Diseases
- Diabetes Complications
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Diabetes Mellitus
- Diabetic Neuropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antioxidants
- Resveratrol
Other Study ID Numbers
Other Study ID Numbers
- University of Sulaimani (Other Identifier: College of Pharmacy)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.